12:00 AM
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Increlex mecasermin: Phase IIIb data

In the 12-month, open-label Phase IIIb MS301 trial in 136 patients with primary IGFD, twice-daily Increlex met the primary endpoint of a significant increase in first-year height velocity compared with untreated controls. Data were presented at the International Congress of Endocrinology in...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >